Johnson & Johnson has announced that it is acquiring privately-held, clinical-stage biopharma Novira Therapeutics, but has kept financial details of the deal firmly under wraps.
The move gives the healthcare giant access to Novira’s portfolio of novel antivirals for the treatment of chronic hepatitis B virus (HBV) infection, which affects 350 million – 400 million people worldwide, including lead candidate NVR 3-778.
NVR 3-778 is a small molecule, direct acting antiviral, that inhibits the HBV core, a new and promising drug target involved in multiple activities required for viral replication and persistence.
The orally-administered drug “offers the potential for efficient suppression of virus production and replication, which could help address the remaining unmet medical needs,” says J&J.
The transaction is expected to close during the fourth quarter of 2015.
Source: Pharma Times
Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.
Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.
In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.